Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB)

NCT04979130 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide, compared to a placebo, affects intestinal barrier function in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind basic-science study

Participants 69 people

Who can join Ages 18–89 · all sexes

Timeline Started 2022-01 · est. completion 2024-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT04979130 ↗

Description as written by the study sponsor.

This study plans to learn more about the effect of semaglutide once weekly on intestinal permeability in individuals with type 2 diabetes.

Treatments tested

Semaglutide also known as Ozempic, PDS290 pen-injector Drug

Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
Placebo also known as PDS290 pen-injector Drug

Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Main thing measured	Differences in lactulose mannitol ratio (LMR) test as a measure of intestinal permeability between treatment groups
Sponsor	University of Colorado, Denver
Conditions studied	Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04979130 ↗